Truist Securities Maintains Buy on Keros Therapeutics, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Srikripa Devarakonda maintains a Buy rating on Keros Therapeutics (NASDAQ:KROS) with a $100 price target.
June 18, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Srikripa Devarakonda maintains a Buy rating on Keros Therapeutics with a $100 price target.
The reaffirmation of a Buy rating and a $100 price target by Truist Securities is a positive signal for investors, likely boosting short-term confidence and demand for Keros Therapeutics' stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100